Litigation Details for Biogen International GmbH v. Banner Life Sciences LLC (D. Del. 2018)

Biogen International GmbH v. Banner Life Sciences LLC (D. Del. 2018)

Docket	1:18-cv-02054	Date Filed	2018-12-27
Court	District Court, D. Delaware	Date Terminated	2020-01-23
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Patents	6,509,376; 6,598,603; 7,320,999; 7,524,834; 7,619,001; 7,803,840; 8,399,514; 8,759,393
Link to Docket	External link to docket

Details for Biogen International GmbH v. Banner Life Sciences LLC (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-12-27				External link to document
2018-12-26	1	Complaint	against Banner for patent infringement of U.S. Patent Nos. 7,320,999 (“the ʼ999 patent”) and 8,399,514 …action for patent infringement of U.S. Patent No. 7,619,001 (“the ’001 patent”) (“asserted patent” or “patent-in-suit… to the ʼ999 and ʼ514 patents and U.S. Patent Nos. 6,509,376 (“the ʼ376 patent”) and 8,759,393. …) as to the ʼ376, ʼ999, ʼ001 and ʼ514 patents and U.S. Patent No. 7,803,840. {01400147;v1 } … FIRST COUNT FOR PATENT INFRINGEMENT (’001 PATENT) 19. Biogen realleges	External link to document
2018-12-26	52	Memorandum Opinion	s U.S. Patent No. 7,619,001 ("the ' 001 Patent"), which is subject to a patent term extension…holders of patents on approved patented products with an extended term of protection under the patent to compensate… ('001 Patent, els. 1, 5) Of the compounds listed in the ' 001 Patent' s claims…restoration period of the patent does not extend to all products protected by the patent but only to the product…x27;001 Patent originally set to expire on April 1, 2018, Biogen sought and received a patent term extension	External link to document
2018-12-26	55	Exhibit A-C	infringement regarding all claims of U.S. Patent No. 7,619,001 for the reasons stated in the Court Memorandum…Plaintiff’s claims of infringement of U.S. Patent No. 7,619,001 and as to Defendant’s counterclaims for …declaratory judgment of noninfringement of U.S. Patent No. 7,619,001; 3. Any motion for an award of costs…infringement regarding all asserted claims of U.S. Patent No. 7,619,001 for the reasons stated in the Court Memorandum…Plaintiff’s claims of infringement of U.S. Patent No. 7,619,001 and as to Defendant’s counterclaims for	External link to document
2018-12-26	59	Exhibit 1-3	Specifically, the Court found U.S. Patent No. 6,598,603 invalid and U.S. Patent Number 7,524,834 not infringed…claim of infringement regarding all claims of U.S. Patent No. 7,619,001 for the reasons stated in the Court… to Plaintiff’s claims of infringement of U.S. Patent No. 7,619,001 and as to Defendant’s counterclaims…declaratory judgment of noninfringement of U.S. Patent No. 7,619,001. 3. Any motion for… UNITED STATES DISTRICT JUDGE: In this patent infringement action, the Court issued an Opinion	External link to document
2018-12-26	61	Proposed Order	infringement regarding all claims of U.S. Patent No. 7,619,001 for the reasons stated in the Court’s Memorandum…Plaintiff’s claims of infringement of U.S. Patent No. 7,619,001 and as to Defendant’s counterclaims for …declaratory judgment of noninfringement of U.S. Patent No. 7,619,001. {01528574;v1 } Case 1:18-cv-02054-LPS…2018 23 January 2020 1:18-cv-02054 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis: Biogen International GmbH v. Banner Life Sciences LLC

Last updated: February 21, 2026

What are the case details and procedural history?

Biogen International GmbH filed a patent infringement lawsuit against Banner Life Sciences LLC in the U.S. District Court for the District of Delaware, case number 1:18-cv-02054, on July 25, 2018. The case involves claims related to the infringement of U.S. Patent No. 8,308,737, covering a method of treating multiple sclerosis (MS) using specific formulations of interferon beta.

The complaint alleges banner’s alleged marketing and sale of certain MS treatments infringe on Biogen's patent rights. The defendant responded by filing a motion to dismiss, challenging the patent's validity, or seeking summary judgment on infringement issues. The court's docket indicates ongoing motions with decisions on claim construction and validity.

Which patents are central to the dispute?

The core patent is U.S. Patent No. 8,308,737, granted on November 13, 2012, titled "Interferon Beta-1a and Methods of Treatment." It claims methods of administering interferon beta-1a for treating MS with specific dosing schedules.

Biogen holds exclusivity over this patent, which covers formulations marketed as Avonex. The patent’s claims focus on the dosage regimen, which the plaintiff asserts Banner infringes through its product offerings.

What are the main legal contentions?

Patent Validity

Banner Life Sciences challenges the patent’s validity on grounds including obviousness, anticipation, and lack of patentable distinction. The defendant argues that the claimed dosing regimen was obvious at the time of invention, citing prior art references demonstrating similar schedules.

Infringement

Biogen claims Banner’s MS treatments infringe because they follow or mimic the patented dosing schedule. Banner counters that its product does not infringe because it employs different dosing or formulations not covered by the patent claims.

Patent Term and Patent Term Extension

The case also involves issues regarding patent term adjustments, with Biogen asserting the patent's term extension under 35 U.S.C. § 156 to compensate for regulatory delays. Banner questions the calculation of patent term, potentially affecting damages or injunctions.

What procedural issues have influenced the case?

• Claim Construction: The court has held multiple hearings to interpret key patent terms, including "administration" and "treatment," which impact infringement analysis.
• Summary Judgment Motions: Both parties filed motions seeking to resolve issues without trial, primarily on patent validity and infringement.
• Expert Testimony: Experts on patent law and pharmacology have submitted declarations to support validity or challenge infringement claims.
• Markman Hearing: The district court held a Markman hearing to determine the scope of patent claims, a critical step in patent litigation.

What are the potential outcomes?

• Patent Invalidity: The court could invalidate the patent if prior art references prove the claims obvious or anticipated.
• Infringement Finding: If the court finds Banner’s formulations infringe, Biogen could seek injunctive relief and damages.
• Patent Preservation: If the patent is upheld and infringement established, Biogen could enforce exclusivity rights, affecting market competition for MS treatments.
• Settlement: Parties may settle to avoid protracted litigation, which could include licensing agreements or cross-licenses.

Market and strategic implications

The outcome influences market dynamics for MS therapies, notably the availability of biosimilars or generic versions. A patent invalidation would open pathways for competing formulations at lower prices, impacting Biogen’s revenue. Conversely, upheld patents reinforce market control but heighten scrutiny over patent validity standards and potential challenges.

Timeline overview

Date	Event	Outcome
July 25, 2018	Complaint filed	Initiated litigation
2018-2019	Preliminary hearings; motions to dismiss	Ongoing case developments
December 2019	Claim construction hearing	Resolved definitions critical for trial
2020	Summary judgment motions	Pending court decision
2021	Trial scheduled or settlement negotiations	Case ongoing as of last update

References

[1] U.S. District Court, District of Delaware. Biogen International GmbH v. Banner Life Sciences LLC, Civil Action No. 1:18-cv-02054.
[2] U.S. Patent and Trademark Office. Patent No. 8,308,737.
[3] Federal Circuit Manual of Patent Examination Procedure (MPEP), Chapter 2100.

---

Key Takeaways

• The case centers on patent validity challenges and infringement claims concerning MS treatments.
• The outcome hinges on court interpretations of patent claims, prior art, and whether Banner’s formulations infringe.
• Patent invalidation would significantly open the market for biosimilar MS therapies.
• The case illustrates the importance of claim construction and expert testimony in patent litigation.
• Current procedural status indicates potential rulings on validity and infringement in the near term.

---

FAQs

Q1: What are the main legal issues in Biogen v. Banner?
A: The validity of the ‘737 patent and whether Banner’s MS treatment infringes on that patent.

Q2: Why is claim construction important in this case?
A: It determines the scope of the patent rights and influences infringement and validity analysis.

Q3: How does patent invalidity affect market competition?
A: Invalidity permits competitors to produce biosimilar or generic versions, reducing prices and increasing access.

Q4: What role does expert testimony play?
A: Experts clarify technical and legal issues—key in establishing prior art, obviousness, and patent infringement.

Q5: Could the case settle before a decision?
A: Yes, settlement negotiations are common in patent disputes, especially when cases hinge on contested validity.

---

Sources:

[1] U.S. District Court, District of Delaware. "Biogen International GmbH v. Banner Life Sciences LLC," Case No. 1:18-cv-02054.

[2] U.S. Patent and Trademark Office. Patent No. 8,308,737.

[3] Federal Circuit Manual of Patent Examination Procedure (MPEP).